子苏子汤通过PI3K/AKT1/mTOR、JAK2/STAT3和HIF-1α/NF-κB通路改善咳嗽变异性哮喘大鼠气道高反应性
本研究结合网络药理学与UHPLC-MS/MS分析子苏子汤成分,并在卵清蛋白/氢氧化铝致敏的咳嗽变异性哮喘大鼠模型中验证其作用机制。结果显示子苏子汤可缓解咳嗽症状、降低嗜酸性粒细胞百分比、改善肺组织病理,并通过干扰PI3K/AKT1/mTOR、JAK2/STAT3及HIF-1α/NF-κB通路抑制细胞因子和IgE释放,从而减轻气道高反应性并部分逆转气道重塑。
要点
- 子苏子汤可缓解CVA大鼠咳嗽症状、降低EOS%并改善肺组织病理。
- 其机制涉及抑制PI3K/AKT1/mTOR、JAK2/STAT3和HIF-1α/NF-κB通路。
- 网络药理学提示子苏子汤与CVA共有276个靶点,UHPLC-MS/MS检出52种主要化学成分。
核心结论
- 子苏子汤通过抑制PI3K/AKT1/mTOR、JAK2/STAT3和HIF-1α/NF-κB信号通路改善咳嗽变异性哮喘大鼠气道高反应性并部分逆转气道重塑。
研究设计与样本
- 研究采用网络药理学预测子苏子汤治疗咳嗽变异性哮喘的靶点,并以UHPLC-MS/MS检测子苏子汤的主要化学成分。
- 动物实验采用卵清蛋白/氢氧化铝致敏建立咳嗽变异性哮喘大鼠模型,评估咳嗽症状、嗜酸性粒细胞百分比、肺功能、组织病理、血细胞因子及mRNA和蛋白水平。
主要发现
- 网络药理学提示子苏子汤与咳嗽变异性哮喘共有276个靶点,且子苏子汤治疗咳嗽变异性哮喘与PI3K/AKT信号通路密切相关。
- UHPLC-MS/MS显示子苏子汤含有52种主要化学成分。
- 与模型组相比,不同浓度子苏子汤组大鼠咳嗽症状缓解、嗜酸性粒细胞百分比降低、体重增加。
- HE染色显示子苏子汤减轻气道炎症、水肿和增生,改善肺组织病理结构,高剂量子苏子汤效果尤为显著。
- 子苏子汤通过干扰PI3K/AKT1/mTOR和JAK2信号因子,阻断HIF-1α、STAT3和NF-κB进入细胞核,抑制细胞因子和免疫球蛋白E释放,从而降低气道高反应性并部分逆转气道重塑。
临床怎么用
- 子苏子汤作为临床用于咳嗽和哮喘(尤其咳嗽变异性哮喘)的中药复方,本研究为其改善气道高反应性提供了实验依据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
ETHNOPHARMACOLOGICAL RELEVANCE: Cough-variant asthma (CVA) is one of the most common causes of chronic cough. Its pathogenesis is closely related to chronic airway inflammation and airway hyperresponsiveness. CVA belongs to the category of "wind cough" in Traditional Chinese medicine (TCM). Zi-Su-Zi decoction (ZSD) is a Chinese herbal formula that is clinically used for the treatment of cough and asthma, especially CVA. However, the mechanism of action remains unclear. AIM OF THE STUDY: In this study, we aimed to explore the potential mechanism by which ZSD improves CVA airway hyperresponsiveness. MATERIALS AND METHODS: The targets of ZSD in CVA were studied using a Network pharmacology. The main chemical components of ZSD were detected and analyzed using ultra-high-pressure liquid chromatography (UHPLC-MS/MS). In animal experiments, the rat model of CVA was established using Ovalbumin (OVA)/Aluminum hydroxide (AL(OH)3) sensitization. Moreover, the experiment also evaluated cough symptoms, percentage of eosinophils (EOS%), pulmonary function tests, histopathological sections, blood cytokine levels, mRNA and protein levels. RESULTS: The results showed that Network pharmacology suggested 276 targets of ZSD and CVA and found that ZSD treatment with CVA was closely related to the phosphoinositide 3-kinase (PI3K)/protein kinase B (AKT) signaling pathway. UHPLC-MS/MS revealed that ZSD contained 52 main chemical components. Compared with the model group, the cough symptoms of the rats in the different ZSD concentration groups were relieved, the EOS% index was lowered, and body weight was increased. HE staining showed that ZSD reduced airway inflammation, edema and hyperplasia, thereby improving the pathological structure of lung tissue, and the effect of high-dose ZSD was especially significant. Our most important finding was that ZSD blocked the entry of hypoxia-inducible factor-1α (HIF-1α), signal transducer and activator of transcription-3 (STAT3) and nuclear factor kappa-B (NF-κB) into the nucleus by interfering with PI3K/AKT1/mechanistic target of rapamycin (mTOR), and janus kinase 2 (JAK2) signaling factors. Consequently, inhibiting the release of cytokines and immunoglobulin-E, thereby reducing airway hyperresponsiveness (AHR) and partially reverses airway remodeling. CONCLUSIONS: This study showed that ZSD can improve airway hyperresponsiveness and partially reverse airway remodeling by inhibiting the PI3K/AKT1/mTOR, JAK2/STAT3 and HIF-1α/NF-κB signaling pathways. Therefore, ZSD is an effective prescription for the treatment of CVA.
引用
- Nguyen V, Zhang Q, Pan F, et al. Zi-Su-Zi decoction improves airway hyperresponsiveness in cough-variant asthma rat model through PI3K/AKT1/mTOR, JAK2/STAT3 and HIF-1α/NF-κB signaling pathways. J Ethnopharmacol. 2023. PMID: 37187363. doi:10.1016/j.jep.2023.116637
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。